Angiotensin-IV-derived peptidomimetic small molecule
Experimental cognitionsynaptogenesis
Dihexa
Evidence levelHuman evidence
Human evidenceSee evidence
Regulatory statusNot an approved medicine
What you need to know in 20 seconds
What is it?
Angiotensin-IV-derived peptidomimetic small molecule
Research focus
Experimental cognition, synaptogenesis, neurodegeneration research
Human evidence
FDA states it has not identified human exposure data for drug products containing dihexa acetate by any route.
Regulatory status
Not an approved medicine. FDA lists dihexa acetate among bulk substances with significant safety-information gaps; a UNII/GSRS identity record does not imply approval.
Main limitations
Human efficacy, dosing, PK, safety, cognitive enhancement, long-term effects or reliability of retracted foundational mechanism claims.
Safety
Human safety is unknown; foundational mechanism literature also includes a formal retraction.
i
FDA states it has not identified human exposure data for drug products containing dihexa acetate by any route.
What the evidence actually supports
✓Strong 'evidence gap' page: trending claim, no human evidence, retraction warning.
✓Place the integrity warning above mechanistic marketing claims.
✓This should be the first Quick & Clear answer before discussing animal hypotheses.
What is not established / key limitations
×A key 2014 procognitive/c-Met paper was formally retracted in 2025.
×The retracted paper's numerical binding/mechanistic claims must not be repeated as established facts.
×Human dosing, PK, efficacy, interactions and safety are unestablished.
Selected study & evidence records
Retraction notice: procognitive and synaptogenic effects of angiotensin-IV-derived peptides
2025 · Retraction notice
The 2014 paper frequently cited for HGF/c-Met-dependent procognitive/synaptogenic effects was formally retracted in 2025.
The journal retracted the 2014 paper after a Washington State University investigation found falsified and/or fabricated data in figures and related erratum data.
Human safety is unknown; foundational mechanism literature also includes a formal retraction.
Human safety is essentially uncharacterised; FDA lacks important safety information, and the evidence base also includes a formal retraction affecting foundational mechanistic claims.
Technical details
Mechanism / biologyHistorically proposed HGF/c-Met and synaptogenesis mechanisms require a prominent integrity warning because the foundational 2014 paper supporting key HGF-binding/c-Met/procognitive claims was formally retracted in 2025 after falsified/fabricated data were identified.
Route / formulation boundaryNo route has an established human therapeutic safety/dose framework for dihexa itself.
Identity / data-quality noteFoundational 2014 HGF/c-Met Dihexa paper retracted in 2025; do not use it as unqualified supporting evidence.
Dosing evidence statusNo verified human dihexa dosing regimen identified. No human drug-exposure dosing record for dihexa itself was identified; internet dosing protocols should not be presented as evidence.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
